Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Capecitabine in Early Breast Cancer
NCT00114816Phase 3Completed
- Sponsor
- Finnish Breast Cancer Group
- Start
- Jan 2004
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in breast cancer (2 arms), sponsored by Finnish Breast Cancer Group. Primary endpoint: Recurrence-free survival at 5 years. Started Jan 2004; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00114816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114816.